Hillgene is an industrialized and integrated solutions provider for cell therapy products headquartered in Suzhou, China. Hillgene is a comprehensive cell therapy CDMO that provides services for CAR-T, lentiviral vectors, and plasmids from investigator-initiated trials through commercial grade. The company has built a pathway for the development of cell therapy products from discovery to delivery by establishing cellular therapy product–specific platforms for nucleic acid manufacturing, serum-free suspension culturing, closed process development, and QC testing.